All 50 states received federal awards under the new Rural Health Transformation Program, with first-year allocations ranging from $147 million to $281 million to strengthen rural health systems through workforce expansion, health IT modernization, and new delivery models. States now face implementation challenges including reconciling budgets with CMS, building governance structures, finalizing procurement approaches, and balancing rapid spending timelines against thoughtful program design. While the program isn't Medicaid-specific, many states will likely leverage Medicaid managed care delivery systems and payment structures to execute rural health initiatives, creating indirect implications for MCO operations in rural markets.

The U.S. Pharmacopeia's 2026 Drug Classification update revises how drugs are grouped for non-Part D health plan formularies, including Medicaid managed care plans. While primarily focused on Medicare Part D guidance, these classifications influence how all health plans structure formularies and could affect drug eligibility for upcoming Medicare international reference pricing demonstrations. The annual update cycle for non-Part D classifications offers Medicaid plans more frequent opportunities to engage on drug categorization than the three-year Medicare cycle.

CMS's extension of the Acute Hospital Care at Home waiver through 2030 expands opportunities for provider-based acute care delivery in home settings, with potential implications for Medicaid managed care organizations seeking to reduce inpatient costs and improve member experience. While the piece focuses primarily on Medicare fee-for-service hospital waivers, the care model's demonstrated 30% cost reduction and improved outcomes could inform Medicaid MCO network strategies and value-based arrangements with hospital partners. The analysis is hospital-centric but touches on delivery system innovations relevant to managed care populations broadly.

Health plans receiving substance use disorder (SUD) patient data from specialized treatment programs must comply with updated 42 CFR Part 2 regulations by February 16, 2026, including revisions to privacy notices and operational procedures. The regulations now carry HIPAA-level enforcement penalties after being largely unenforced historically, creating new compliance risk for Medicaid managed care organizations that handle SUD data. Plans must update both Part 2 and HIPAA notices of privacy practices to reflect stricter protections for SUD information compared to other health data.

CMS has updated its guidance on State Directed Payments in Medicaid managed care, revising how states can grandfather existing arrangements under new statutory payment caps enacted by Congress. The February 2026 guidance modifies CMS's interpretation of the grandfathering window and affects SDPs for hospital, nursing facility, and academic medical center practitioner services—critical payment mechanisms MCOs use to distribute supplemental payments to providers. This represents a significant shift in federal oversight that will require MCOs and state Medicaid agencies to reassess their SDP arrangements and compliance strategies.

A new CMS final rule restricts how states can structure healthcare-related taxes—especially those targeting managed care organizations—by closing a loophole that allowed higher tax rates on Medicaid-heavy providers. The regulation prohibits states from using utilization tiers or proxy classifications that effectively isolate high-Medicaid-volume entities, affecting nine tax waivers across seven states. For MCO executives and state Medicaid directors, this changes the financing landscape by limiting a common strategy for generating state match dollars tied to managed care arrangements.

California's 58 counties serve as critical administrators and providers within the state's Medi-Cal managed care system, which now covers approximately 15 million members with 95% enrolled in managed care plans. Recent state reforms including CalAIM and BH-CONNECT have significantly expanded county obligations around Enhanced Care Management, Community Supports, behavioral health coordination, and cross-system data reporting. These evolving responsibilities require counties to balance state mandates with local delivery needs while managing both Medi-Cal specialty behavioral health services and safety net programs for vulnerable populations.

SAMHSA's designation of January as National SUD Treatment Month underscores ongoing challenges in substance use disorder treatment access and quality that directly affect Medicaid managed care plans. Despite evidence-based treatment guidelines and locator tools, significant treatment gaps persist, particularly for medication-assisted treatment for opioid and alcohol use disorders—conditions disproportionately affecting Medicaid populations. The commentary frames systemic barriers including inadequate provider networks and treatment system features that MCO compliance teams and behavioral health directors must address to improve recovery outcomes.

CMS Innovation Center has launched seven new alternative payment models focused primarily on Medicare beneficiaries, with three chronic care management models (ACCESS, MAHA-ELEVATE, and LEAD) explicitly offering opportunities for multi-payer integration including Medicaid. Four additional models target drug pricing with one (GENEROUS) specifically aimed at Medicaid, while the existing Integrated Behavioral Health model may expand to additional states. The models align with the administration's prevention-focused MAHA agenda but lack critical implementation details including payment structures.

This discussion examines how Medicaid managed care organizations can better coordinate with child welfare, behavioral health, and other family-serving systems to improve outcomes for children and families—Medicaid's largest user population. The conversation addresses common barriers like agency silos, policy volatility, and capacity constraints that prevent effective cross-system collaboration. For MCO compliance teams and state Medicaid directors, this speaks to growing expectations around care coordination and whole-family approaches in managed care contracting and operations.

Sellers Dorsey provides a state-by-state breakdown of how the new $50 billion Rural Health Transformation Program allocated first-year funding to stabilize rural health systems and expand care access. While the program addresses rural provider infrastructure broadly, it has implications for Medicaid managed care networks that depend on rural providers for network adequacy and member access. The analysis offers state-specific details relevant to MCOs operating in rural service areas or managing provider relationships in underserved regions.

The reconstituted Advisory Committee on Immunization Practices made changes to pediatric immunization schedules in December 2025 and signaled potential 2026 policy shifts affecting vaccines for HPV, RSV, influenza, and pregnancy-related immunizations. Because ACIP recommendations trigger mandatory Medicaid coverage without cost-sharing when published in official immunization schedules, these deliberations—and the committee's altered composition and process—carry direct implications for MCO benefit design, preventive care obligations, and pediatric and maternal health programs. The exclusion of traditional medical society liaisons from work groups may affect the clinical grounding of future recommendations that Medicaid plans must operationalize.

The 340B drug discount program reached $81.4 billion in 2024, with disproportionate share hospitals accounting for 78% of purchases. Many DSH hospitals also participate in Medicaid managed care, and pending federal reforms—including the 340B Rebate Model pilot and congressional bills—could reshape how these entities finance care for Medicaid beneficiaries. The program now exceeds Medicaid drug spending, making potential policy changes significant for state programs and MCOs contracting with 340B-eligible providers.

Major changes to the Advisory Committee on Immunization Practices—including replacement of all members and elimination of expert working groups—may affect Medicaid coverage requirements, since ACIP recommendations trigger mandatory coverage under federal law and determine which vaccines qualify for the Vaccines for Children program. The white paper examines how these structural changes could disrupt the evidence-based processes that underpin Medicaid immunization benefits and patient access protections.

Ten states have implemented and sixteen are considering the Family CNA model, which trains and reimburses family members to provide home care for medically complex children that would otherwise require RN, LPN, or non-family CNA services. Most states implement through mandatory home health or optional private duty nursing state plan benefits, though some use 1915(c) waivers or could use 1115 demonstrations. Oklahoma estimates the model could generate significant annual cost savings while expanding access to care for children with medical complexity.

Sellers Dorsey's CEO argues that recent federal policy changes, including H.R.1, are forcing Medicaid programs to move away from one-size-fits-all models toward community-tailored strategies backed by stronger data analytics and accountability measures. The commentary positions 2025 as an inflection point requiring states and MCOs to demonstrate measurable value, modernize operations, and use technology to target interventions more precisely across diverse populations and geographies.

Manatt Health analyzes the new GENEROUS Model announced by CMS, comparing its pricing metrics to previously used most-favored-nation (MFN) approaches and outlining key design elements and timeline. The piece examines participation opportunities and risks for both pharmaceutical manufacturers and state Medicaid programs, addressing outstanding design questions that affect drug pricing and reimbursement in Medicaid managed care.

CMS achieved an average 62% discount off list prices for 15 drugs in the second cohort of Medicare drug price negotiations, representing a 28% reduction below statutory ceiling prices—nearly double the discount margin achieved in year one. While the negotiation program is Medicare-focused, the outcomes have implications for Medicaid managed care organizations through potential manufacturer price adjustments, best price calculations, and rebate dynamics that could affect MCO pharmacy budgets and formulary strategies. The deeper discounts may also influence cross-program pricing pressure and state supplemental rebate negotiations.

Eight states have established Prescription Drug Affordability Review Boards (PDABs) to control drug costs, with four states (CO, MD, MN, WA) authorized to set Upper Price Limits that typically apply to both Medicaid and state-regulated commercial plans. Colorado became the first state to implement a UPL in October 2025, setting a $600 per-unit cap on Enbrel aligned with federal negotiated pricing. For Medicaid managed care plans operating in these states, PDABs represent a new layer of price regulation affecting pharmacy benefits and potentially reimbursement structures for approximately 7.8 million covered lives.

CMS's Rural Health Transformation (RHT) Program is directing significant federal funding to states to improve rural healthcare infrastructure, workforce, and services, with Medicaid agencies expected to play a coordinating role. States must design comprehensive rural health initiatives with clear accountability measures, as demonstrated by New Mexico's $1 billion application and Tennessee's $197 million in awarded funding. While the program extends beyond Medicaid to include broader rural health system support, state Medicaid directors will likely be involved in planning and implementation given their role in rural coverage and provider networks.